* required
*=required
Introduction with Keith Miller, PhD
Definitions and Epidemiology; Pathophysiology; Natural History of the Disease; Morbidity and Mortality with Christina Hanson, MS, FNP
Identifying Risk Factors; Patient Identification; Patient Perspective with Ann Moore, FNP-C
Treating Patients With NASH and Significant Fibrosis – Are we doing Enough? with Prof Quentin M. Anstee, MD
Treating Patients With NASH and Significant Fibrosis – Now and in the Future with Prof Jörn M. Schattenberg, MD
Treating Patients With NASH and Significant Fibrosis – What does the Future Hold? with Prof Stephen A. Harrison, MD, FACP, FAASLD
Definitions, Epidemiology & Comorbidities; Pathophysiology with Mazen Noureddin, MD, MHSc
Morbidity & Mortality; Patient Identification; Patient Perspective with Marcelo Kugelmas, MD, FAASLD, FACP
Part I - Fatty Liver Foundation Development with Wayne Eskridge with Wayne Eskridge
Part II - Advice for Patients with Recent Diagnosis of NASH with Fibrosis with Wayne Eskridge
Part III - After Diagnosis: What Happens Now? with Wayne Eskridge and Scott L. Friedman, MD